LBA3 Safety and efficacy of pembrolizumab combined with paclitaxel and cisplatin as a neoadjuvant treatment for locally advanced resectable (stage III) esophageal squamous cell carcinoma (Keystone-001): Interim analysis of a prospective, single-arm, single-center, phase II trial

• DOI: 10.1016/j.annonc.2021.10.218
• Publication Date: 2021-12-10T14:13:41Z
• Authors: X. Shang; C. Zhang; G. Zhao; W. Zhang; L. Liu; X. Duan; J. Yue; Z. Ma; C. Chen; B. Meng; X. Ren; H. Jiang
• Keywords: Neoadjuvant Therapy; Interim analysis